

Jiangsu Hengrui Medicine Co., Ltd. donates \$30,000 to the USCACA for Early Phase Oncology Research Training (EFFORT) Scholarship at the 7th Annual USCACA Meeting at AACR 2015 in Philadelphia


Philadelphia, PA — (May 6, 2015) On April 19, 2015, more than 100 cancer researchers worldwide from academia, industry, and government agencies attended the 7th Annual USCACA Meeting at AACR 2015. In addition to showcasing recent advances in gastric cancer research, the crowd also witnessed the touching moment when Dr. Li Xu, on behalf of the Jiangsu Hengrui Medicine Co., Ltd., passed a \$30,000 check to the USCACA. This special fund is to benefit the USCACA-Hengrui Scholarship Program for Early Phase Oncology Research Training (EFFORT) that supports young Chinese clinicians for their training in the United States.



“This Scholarship Program provides an opportunity for young Chinese investigators to study early phase oncology drug development in top US institutes,” said Dr. Li Xu, SVP of Jiangsu Hengrui Oncology. “Our ultimate goal is to connect China to global oncology drug development and to provide these young clinicians the opportunity for learning, growing, and leading oncology drug development in China and globally.”

“Every year, the USCACA-Hengrui Scholarship Program Committee selects clinicians from China to come to the States to understand the entire process and relevant regulations of developing novel oncology drugs in clinic and more importantly, appreciate the scientific,

medical and operational aspects of early stage clinical trials (e.g., phase 1 or 2),” said Dr. Shi-Yuan Cheng, President of the USCACA. “Thanks to Jiangsu Hengrui, the leading oncology specialty company in China, who inspires and supports the program like **EFFORT**, we are able to advance the USCACA’s mission to facilitate collaboration among cancer researchers and physicians in the United States and China”.



It is anticipated that after completed their training in the US, the clinicians will be equipped with knowledge and insights to further improve the capability in conducting early phase trials, which are urgently needed in China. With Hengrui’s sponsorship, Ms. Gan Bin has accomplished her training at Wisconsin Comprehensive Cancer Center (WCCC) and Moffitt during 2013-2014, who is currently engaged in multiple clinical trials in China. Subsequently, Dr. Jingji Yang has completed his rotation at WCCC, CTEP/NCI and MD Anderson Cancer Center.

“The USCACA is known for bringing great cancer researchers, scientists, and experts from pharmaceutical industries as well as academic and government agencies together for a common goal, accelerating collaboration between US and China to facilitate clinical research and development in oncology in China. To do so, the first and the most important step is for Chinese doctors and nurses to know how to conduct a clinical trial that meets the global standards.” said Lianshan Zhang, (VP and Global Head of R&D of Hengrui) of Jiangsu Hengrui Medicine Co., Ltd. “Hengrui is very proud to partner with the USCACA to pave such a driveway to achieve our common goal.”

USCACA also wants to take this opportunity to thank the following individuals for their support the Hengrui-USCACA Scholarship.

Dr. George Wilding and Ms. Dona Alberti, University Wisconsin Comprehensive Cancer Center

Drs. Wei Sheng and Dan Sullivan, Moffitt Cancer Center

Drs. Helen Chen and Pamela Harris, CTEP/NCI

Drs. David Hong, Funda Meric-Bernstam, Denise De La Cruz, and Sarina Anne Piha-Paul, MDACC

The program would not be possible without the generous grant from Jiangsu Hengrui Co. and USCACA want to thank Mr. Piaoyang Sun, Drs. Li Xu and Lianshan Zhang for their support of the program.

The EFFORT program will be rolled out officially in July. Please follow the progress on Chinese Journal of Cancer, and USCACA website.

